The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

Novo Nordisk forecasts 2025 sales growth will slow, citing increased competition for its obesity drug Wegovy and aligning ...

Genetic engineering deployed to insert gene for human insulin into a bacterium, thus harnessing the substance for widespread ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Toyota Motor sold 10.8 million vehicles globally in 2024, retaining its position as the world's biggest carmaker. The Japanese automakers had announced a plan to combine in December. Novo's Wegovy and ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

WEC Energy Group Inc (WEC) reports robust earnings growth and unveils a historic $28 billion capital plan, while navigating ...